NCT02842333View on ClinicalTrials.gov

Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor

NACompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 6, 2020

Study Completion Date

October 6, 2020

Conditions
Chronic Leukemia
Interventions
OTHER

Additional biological samples

Blood samples

Trial Locations (4)

Unknown

Centre Hospitalier Régional Universitaire de Besançon, Besançon

CHU de Dijon, Dijon

CHU de Nice, Nice

Hôpital Saint-Louis, Paris

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT02842333 - Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor | Biotech Hunter | Biotech Hunter